Sugi Predict

Sugi Predict / Compounds / SCHEMBL24252328

SCHEMBL24252328

SCHEMBL24252328

COc1ccc(CNc2nnc(C)c3cc(-c4cc(Cl)c(F)cc4OC)ccc23)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 18/20 0.47
▸ CYP3A4 P08684 18/20 0.47
▸ CYP2C19 P33261 16/20 0.47
▸ TSHR P16473 13/20 0.47
▸ ALDH1A1 P00352 12/20 0.47
▸ HSD17B10 Q99714 12/20 0.47
▸ CLK4 Q9HAZ1 11/20 0.47
▸ CYP2C9 P11712 10/20 0.47
▸ LMNA P02545 9/20 0.47
▸ CYP2D6 P10635 14/20 0.44
▸ HIF1A Q16665 6/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ USP2 O75604 7/20 0.43
▸ MAPK1 P28482 6/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPT P10636 4/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MEN1 O00255 6/20 0.43
▸ KMT2A Q03164 6/20 0.43
▸ ALOX15 P16050 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24252798 0.91 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30451356 0.91 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30451432 0.89 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30453283 0.89 CYP1A2 (0.46) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL24252827 0.89 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL24252854 0.89 CYP1A2 (0.46) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30451971 0.88 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL24252327 0.88 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL24252899 0.88 CYP1A2 (0.44) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30452067 0.88 CYP1A2 (0.44) CYP1A2CYP3A4CYP2C19TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 — — US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 — — US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 — — CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 — — CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 — — EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 — — US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH CYP1A2 4150/4885CYP3A4 4043/4885CYP2C19 3592/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 CYP1A2 3838/4885CYP3A4 3719/4885CYP2C19 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.